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Neuroﬁbromatosis 2 (NF2) is an autosomal dominant disease that is characterized by tumors on the vestibular
branch of the VIII cranial nerve, but other types of nervous system tumors usually occur as well. Genotype-phenotype
correlations are well documented for overall NF2 disease severity but have not been deﬁnitively evaluated for speciﬁc
types of non–VIII nerve tumors. We evaluated genotype-phenotype correlations for various types of non–VIII nerve
tumors in 406 patients from the population-based United Kingdom NF2 registry, using regression models with the
additional covariates of current age and type of treatment center (specialty or nonspecialty). The models also
permitted consideration of intrafamilial correlation. We found statistically signiﬁcant genotype-phenotype corre-
lations for intracranial meningiomas, spinal tumors, and peripheral nerve tumors. People with constitutional NF2
missense mutations, splice-site mutations, large deletions, or somatic mosaicism had signiﬁcantly fewer tumors than
did people with constitutional nonsense or frameshift NF2 mutations. In addition, there were signiﬁcant intrafamilial
correlations for intracranial meningiomas and spinal tumors, after adjustment for the type of constitutional NF2
mutation. The type of constitutional NF2 mutation is an important determinant of the number of NF2-associated
intracranial meningiomas, spinal tumors, and peripheral nerve tumors.
Introduction
Neuroﬁbromatosis 2 (NF2 [MIM 101000]) is an auto-
somal dominant disease that is caused by inactivatingmu-
tations of the NF2 tumor-suppressor gene (Rouleau et al.
1993; Trofatter et al. 1993). The clinical abnormalities of
NF2 may include vestibular schwannomas (typically bi-
lateral), intracranial meningiomas, spinal tumors, periph-
eral nerve tumors, and ocular abnormalities, such as pre-
senile cataracts (Evans et al. 1992a; Parry et al. 1994;
Mautner et al. 1996b). Genotype-phenotype correlations
for overall NF2 disease severity were ﬁrst reported in
1995, soon after the identiﬁcation of the NF2 gene; by
1998, these correlations were well established. In general,
constitutional NF2 nonsense or frameshift mutations are
associated with severe NF2, and missense mutations, in-
frame deletions, and somatic mosaicism are associated
with mild NF2 (Me´rel et al. 1995; Kluwe et al. 1996,
1998; Parry et al. 1996; Ruttledge et al. 1996; Evans et
al. 1998a, 1998b; Kluwe and Mautner 1998).
Initial genotype-phenotype correlation studies of
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NF2 were limited by the generality of the deﬁnition of
disease severity, which was often reported only as
“mild,” “moderate,” or “severe.” The mild and severe
disease categories correspond to the historical nomen-
clature of “Gardner” (mild) and “Wishart” (severe)
subtypes, which were based on the clinical observation
that the severity of NF2 tends to “run true” within a
family (Wishart 1822; Gardner and Frazier 1930). An-
other category, “Lee-Abbott,” which corresponds to
very severe NF2, was not consistently adopted by sub-
sequent studies (Lee and Abbott 1969).
More recent genotype-phenotype correlation studies
tend to use indices, such as age at onset of symptoms of
NF2, that portray the continuum of overall disease se-
verity. Age at onset of symptoms reﬂects the burden of
the many different types of clinical abnormalities in NF2.
In patients with NF2 who present symptomatically, the
initial symptom is related to vestibular schwannomas in
1/3 to 2/3 of patients (Evans et al. 1992a; Parry et al.
1994; Mautner et al. 1996b). Patients with NF2 whose
initial symptom occurs in adulthood tend to present with
VIII nerve symptoms, whereas the initial symptom of
children with NF2 is often related to clinical abnor-
malities other than vestibular schwannomas (Mautner
et al. 1993; MacCollin and Mautner 1998; Evans et al.
1999; Nunes and MacCollin 2003).
Parry et al. (1994) used age at onset of NF2 symptoms
as a criterion to deﬁne overall disease severity (aged !20
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years, severe disease; aged20 years, mild disease). The
importance of age at onset of NF2 symptoms as a pre-
dictor of subsequent disease course has been validated
in longitudinal studies. Age at onset of symptoms or
age at diagnosis are the most important predictors of
vestibular schwannoma growth rates in NF2 (Baser et
al. 2002b; Mautner et al. 2002) and of the risk of death
in patients with NF2 (Baser et al. 2002a; Otsuka et al.
2003).
In the past decade, NF2 mutation analysis techniques
have been reﬁned, and the deﬁnition of the clinical spec-
trum of NF2 has been broadened. However, genotype-
phenotype correlation studies have been based on rela-
tively few patients because of the rarity of the disease
(Evans et al. 1992b), and genotype-phenotype correla-
tions have been established only for overall NF2 disease
severity, not for the various types of non–VIII nerve tu-
mors that often occur in NF2. In the present study, we
found genotype-phenotype correlations for the number
of NF2-associated intracranial meningiomas, spinal tu-
mors, and peripheral nerve tumors. We also found sig-
niﬁcant correlations within families for intracranial men-
ingiomas and spinal tumors.
Methods
Patients
Data for this study were obtained from the popula-
tion-based United Kingdom NF2 registry (Department
of Medical Genetics, St. Mary’s Hospital, Manchester).
Patients with NF2 are ascertained by contacting neuro-
surgeons, otolaryngologists, neurologists, pediatricians,
dermatologists, and geneticists throughout the United
Kingdom, augmented in the North West Region by the
Regional Cancer Registry. The study was subject to con-
tinuing ethics committee evaluation, and patients con-
sented to participation.
People were eligible for inclusion if they met theMan-
chester clinical diagnostic criteria for NF2 (Evans et al.
1992a) ( ) or did not meet these criteria but hadnp 394
an identiﬁed constitutional NF2 mutation ( ). Wenp 12
included only those patients who had been screened for
constitutional NF2 mutations and had available clinical
information from imaging studies of intracranial men-
ingiomas, had spinal tumors or tumors of cranial nerves
other than the VIII nerve, or had available clinical infor-
mation from physical examination on peripheral nerve
tumors. The analysis excluded several groups with too
few people to analyze separately: somatic mosaics who
had identiﬁed NF2 mutations other than nonsense or
frameshift mutations ( ) and people with consti-np 8
tutional NF2 in-frame deletions ( ) or chromoso-np 3
mal translocations involving the NF2 locus ( ). Thenp 3
406 people included in the study were from 267 families
(247 people with newmutations and 159 inherited cases;
200 females and 206 males). There were data for 389
people with intracranial meningiomas, 351 people with
spinal tumors, 332 people with peripheral nerve tumors,
and 319 people with tumors of cranial nerves other than
the VIII nerve (278 people had all four types of tumors).
The analyses for each type of tumor were based on the
people who had data for that speciﬁc type of tumor.
Detection of NF2 Mutations
Samples were tested for the presence of point mu-
tations by direct sequencing of Meta-PCR products
(Wallace et al. 1999). The entire cDNA of the NF2
gene was covered in four Meta-PCR reactions. Gel-
puriﬁed Meta-PCR products were then sequenced in
both orientations by use of BigDye v2 chemistry, ac-
cording to the manufacturer’s instructions. Sequencing
electropherograms were scanned for mutations by use
of the trace subtraction algorithm “TraceDiff,” which
is available as a component of the Staden package. In
samples in which mutations were identiﬁed, the pres-
ence of mutations was conﬁrmed by use of the genomic
DNA sample for repetition of the Meta-PCR ampliﬁ-
cation and both sequencing reactions. Large deletions,
nonsense mutations, frameshift mutations, and muta-
tions affecting invariate splice-site sequences were as-
sumed to be pathogenic. Missense changes were de-
ﬁned as pathogenic if they had been published and
shown to affect NF2 expression or function. For other
missense changes, parental samples were analyzed; if
the mutation arose de novo in the patient, this was
taken as strong evidence of pathogenicity.
Dosage analysis was performed using a quantitative
PCR-based assay in 10-mL volumes with 100 ng ge-
nomic DNA. Exons 1, 4, 8, and 15 from the NF2 gene
and three amplicons derived from the cystic ﬁbrosis gene
were ampliﬁed within a multiplex PCR. The NF2 prim-
ers and control primers all had identical “universal” for-
ward and reverse sequences at their 5′ termini and were
present at low concentration in the PCR reaction (50
nM). Universal forward and reverse primers were also
included but at a higher concentration (0.5 mM) than the
genomic-speciﬁc primers. The universal forward primer
was 5′-labeled with the ﬂuorescent dye FAM, thereby
allowing ﬂuorescent quantiﬁcation of the PCR products
from each amplicon. The PCR reactions were arrested
at 23 cycles to maintain the ampliﬁcation reactionwithin
the logarithmic phase. Electrophoresis and quantitative
measurement of yield of each product was performed on
an ABI3100 Genetic Analyzer with Genescan and Geno-
typer software. Relative peak heights of all amplicons
of each test sample were compared with a normalized
average of ﬁve negative controls by use of the dosage
quotient (DQ) method (Yau et al. 1996). Calculations
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Table 1
Characteristics of 406 People with NF2, by Type of NF2 Mutation
TYPE OF NF2 MUTATION
Splice
Site Missense
Large
Deletion
Unfound Mutations
Nonsense or Frameshift
Inherited
Cases
People with New
Mutations, with Age
at Onset of
Symptoms
CHARACTERISTIC Classical Somatic Mosaic !20 years 20 years
No. of people/families 111/75 23 78/39 26/8 48/20 25/7 29 66
Age in years (meanSD):
At onset of symptomsa 1912 3011 2312 3217 2413 2213 138 3612
At diagnosis 2313 3711 2815 4121 2814 2613 2210 4313
Vestibular schwannoma (%):
None 7 0 13 0 2 13 3 3
Unilateral 6 26 3 19 4 0 3 20
Bilateral 87 74 84 81 94 87 94 77
Intracranial meningioma (%) 53 65 38 22 42 30 62 48
Peripheral nerve tumors (%) 66 39 52 25 54 79 75 39
Spinal tumors (%) 69 57 47 57 33 62 73 45
Tumors of non–VIII nerve cranial nerves (%) 45 27 33 24 39 28 54 28
a Excludes 20 inherited cases who were asymptomatic at the time of diagnosis of NF2.
were performed onMicrosoft Excel spreadsheetswritten
speciﬁcally for this purpose. A sample from a patient
with an NF2 deletion was included as a control within
each run of samples. If only a single NF2 measurement
showed a DQ measurement within the deleted range
(0.35–0.65), the test was repeated. If results of the re-
peated test agreed with the ﬁrst result, the deleted exon
was ampliﬁed and sequenced with primers that lay ex-
ternal to the dosage primer binding sites, to exclude the
possibility that a polymorphism of the primer binding
site had affected ampliﬁcation efﬁciency.
Magnetic Resonance Imaging (MRI) of the Brain
and Spine
Each patient had an MRI examination of the brain
and full spinal cord at the time of NF2 diagnosis. Sub-
sequent MRI examinations were performed as indicated
clinically or for purposes of routine follow-up, as de-
termined by the patient’s physician. The brain precon-
trast MRI protocol included sagittal T1-weighted spin
echo imaging (5-mm slices) and axial T2-weighted turbo
spin echo imaging (5-mm slices). The brain postcontrast
protocol included axial T1-weighted spin echo imaging
(3-mm slices through the posterior fossa; 5-mm slices
through the rest of the brain) and coronal T1-weighted
spin echo imaging (5-mm slices through the whole brain).
If the patient had a previous translabyrinthine removal
of a vestibular schwannoma, then the postcontrast axial
3-mm slices were done with fat suppression. The spinal
canal postcontrast MRI protocol included sagittal and
coronal T1-weighted spin echo imaging (4-mm slices).
Axial T1-weighted spin echo images and sagittal T2-
weighted turbo spin echo images also were included, if
indicated. The number of spinal tumors, as counted by
the radiologist (J.E.G.), was conﬁrmed by another phy-
sician (D.G.R.E.), who reread the spinal MRIs.
Statistical Analysis
The cross-sectional associations of the type of consti-
tutional NF2 mutation with the various kinds of nervous
system tumors were assessed by regression models. Nu-
merical maximum likelihood was estimated using the
quasi-Newton method. Computations were performed
using C programs developed at the Department of Sta-
tistics, University of British Columbia.
The models were chosen on the basis of the nature of
the dependent variable. A gamma mixture of negative
binomials model was used to model the association of
the type of constitutionalNF2mutationwith the number
of intracranial meningiomas, spinal tumors, and pe-
ripheral nerve tumors, because the count distribution
of these types of tumors was heavily right skewed. A
probit model was used to evaluate the association of
the type of constitutional NF2 mutation with the pres-
ence or absence of tumors of cranial nerves other than
the VIII nerve. In addition, all of the models had an
exchangeable correlation structure within families that
permitted assessment of intrafamilial effects beyond those
produced by the type of constitutional NF2 mutation.
The other covariates were the potential confounders of
current age (when tumor burden was most recently as-
sessed by MRI) and type of treatment center (specialty
or nonspecialty). The genotype-phenotype correlation
tables present, for each type of NF2 mutation, the av-
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Table 2
Genotype-Phenotype Correlations for Intracranial Meningiomas
Type of NF2 Mutationa
Sample Average of No.
of Intracranial
Meningiomas
Model-Based Estimated
Average of No.
of Intracranial
Meningiomas
95% CI
for Count Ratiosb
Nonsense or frameshift:
Classical NF2 1.2 1.4 1.00c
Somatic mosaic 2.8 2.5 .74–3.85
Splice-site 1.0 .9 .34–1.12
Missense .3 .3 .06–.64
Large deletion .9 1.0 .30–1.43
Unfound mutations:
Inherited cases .7 .8 .22–1.30
People with new mutations:
Age at onset !20 years 1.9 2.2 .77–2.92
Age at onset 20 years 1.6 1.2 .41–1.63
NOTE.—Statistically signiﬁcant results are shown in bold italics.
a Other covariates: Intrafamilial correlation (95% CI .10–.39). Current age (per year):coefficientp .24
1.01 (95% CI 1.00–1.02). Type of treatment center (specialty vs. nonspecialty): .92 (95% CI .61–1.40).
b Compared with people with classical NF2 and nonsense or frameshift mutations.
c Reference group.
erage number or prevalence of tumors in the sample and
the model-based number or prevalence of tumors that
were estimated using maximum likelihood, as described
above.
The type of mutation variable was categorical and
coded as eight binary variables. The variables were in-
dicators of somatic mosaicism (deﬁned at the molecular
level and including only mosaics with nonsense or
frameshift mutations), splice-site mutations, missense
mutations, large deletions, and unfound mutations, each
compared with nonsense or frameshift mutations. Since
a large proportion of patients with NF2 (especially those
with new mutations) have unfound mutations, people
with unfound mutations were divided into three sub-
groups: inherited cases, people with new mutations and
onset of symptoms of NF2 at age !20 years (i.e., severe
disease), and people with new mutations and onset of
symptoms of NF2 at age 20 years (i.e., mild disease).
People who met the Manchester clinical diagnostic
criteria for NF2 (Evans et al. 1992a) and who had full
constitutional NF2 nonsense or frameshift mutations
were the reference group in comparisons between dif-
ferent types of NF2 mutations. Genotype-phenotype cor-
relations were evaluated using tumor count ratios or
relative risks (RR) and their 95% CIs from the models.
Count ratios or RR with 95% CIs that excluded zero
were considered to be statistically signiﬁcant.
Results
The characteristics of the study population are presented
in table 1. People with somatic mosaicism or constitu-
tional NF2 splice-site mutations, missense mutations, or
large deletions were signiﬁcantly older at onset of NF2
symptoms and at NF2 diagnosis than were people with
classical NF2 and constitutional NF2 nonsense or
frameshift mutations. The results of the genotype-phe-
notype–correlation analyses for the various types of ner-
vous system tumors are presented in tables 2–5. Relative
to people with classical NF2 and constitutional nonsense
or frameshift NF2 mutations, there tended to be fewer
tumors in somatic mosaics and in people with constitu-
tional NF2 splice-site mutations, missense mutations,
or large deletions (see appendix [online only] for list
of unique NF2 mutations).
People with classical NF2 and nonsense or frameshift
mutations had a model-based estimated average of 1.4
meningiomas (table 2). There were signiﬁcantly fewer (an
average of 0.3) meningiomas in people with missense
mutations.
There were extensive genotype-phenotype correlations
for peripheral nerve tumors (table 3). People with clas-
sical NF2 and nonsense or frameshift mutations had a
model-based estimated average of 4.0 peripheral nerve
tumors. There were signiﬁcantly fewer peripheral nerve
tumors in somatic mosaics (an average of 1.4) and in
people with splice-site mutations (an average of 1.3),
missense mutations (an average of 1.6), or large dele-
tions (an average of 1.6).
People with classical NF2 and nonsense or frameshift
mutations had a model-based estimated average of 4.1
spinal tumors (table 4). There were signiﬁcantly fewer
spinal tumors in people with splice-site mutations (an
average of 2.1) or large deletions (an average of 0.8).
There were fewer spinal tumors in somatic mosaics, but
not signiﬁcantly so.
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Table 3
Genotype-Phenotype Correlations for Peripheral Nerve Tumors
Type of NF2 Mutationa
Sample Average of No.
of Peripheral Nerve
Tumors
Model-Based Estimated
Average of No.
of Peripheral Nerve
Tumors
95% CI
for Count Ratiosb
Nonsense or frameshift:
Classical NF2 3.6 4.0 1.00c
Somatic mosaic 1.4 1.4 .16–.73
Splice-site 1.3 1.3 .19–.58
Missense 1.5 1.6 .18–.93
Large deletion 1.6 1.6 .21–.79
Unfound mutations:
Inherited cases 2.6 2.8 .33–1.44
People with new mutations:
Age at onset !20 years 4.1 4.3 .58–2.02
Age at onset 20 years 1.4 1.4 .20–.60
NOTE.—Statistically signiﬁcant results are shown in bold italics.
a Other covariates: Intrafamilial correlation (95% CI .03 to .29). Current age (percoefficientp .13
year): .99 (95% CI .98–1.01). Type of treatment center (specialty vs. nonspecialty): 1.19 (95% CI .75–1.87).
b Compared with people with classical NF2 and nonsense or frameshift mutations.
c Reference group.
Tumors occurred on all cranial nerves other than the
VIII nerve but were most common on the V nerve (13%
of subjects), the XII nerve (7%), and the II, VII, and X
nerves (3%–4% each). Tumors of cranial nerves other
than the VIII nerve were analyzed in the aggregate, be-
cause the prevalence of tumors on individual cranial
nerves was low. In people with classical NF2 and non-
sense or frameshift mutations, the model-based esti-
mated prevalence of tumors of cranial nerves other than
the VIII nerve was 45% (table 5). There were not sig-
niﬁcant genotype-phenotype correlations.
In addition to genotype-phenotype correlations for
speciﬁc types of mutations, people with new unfound
mutations and older age at onset of symptoms tended
to have milder disease than people with classical NF2
and nonsense or frameshift mutations. Compared with
the reference group, peoplewith newmutations andolder
age at onset of symptoms had a signiﬁcantly lower
model-based estimated number of peripheral nerve tu-
mors and spinal tumors (tables 3 and 4). The model-
based estimated prevalence of tumors of cranial nerves
other than the VIII nerve was lower, but not signiﬁcantly
so.
Other covariates contributed signiﬁcantly to themod-
els for meningiomas and spinal tumors, after adjustment
for the type of constitutional NF2 mutation. There were
signiﬁcant intrafamilial correlations for meningiomas (an
average of 0.24) and spinal tumors (an average of
0.21). The number of meningiomas increased signiﬁ-
cantly with increasing age (1.01 per year of age), and
there were signiﬁcantly more spinal tumors on average
(2.4) in people who were seen in specialty centers than
in those who were seen in nonspecialty centers.
Discussion
There are genotype-phenotype correlations for the num-
ber of NF2-associated intracranial meningiomas, spinal
tumors, and peripheral nerve tumors. These results ex-
tend the genotype-phenotype correlations that have been
reported for overall NF2 disease severity (Me´rel et al.
1995; Kluwe et al. 1996, 1998; Parry et al. 1996; Rutt-
ledge et al. 1996; Evans et al. 1998a, 1998b; Kluwe and
Mautner 1998). The present study and other genotype-
phenotype correlation studies that used data from the
United Kingdom NF2 registry (Evans et al. 1998a; Baser
et al. 2003) are based on patient information from a
variety of types of clinics throughout the United King-
dom, whereas other such studies often have been based
on patients from neuroﬁbromatosis clinics (Me´rel et al.
1995; Kluwe et al. 1996, 1998; Parry et al. 1996; Rut-
tledge et al. 1996). Studies that are based on patients
from specialty clinics may be biased toward people with
more severe disease, and there may be other biases from
specialized referral patterns.
Intracranial meningiomas occur in about half of pa-
tients with NF2 (Evans et al. 1992a; Parry et al. 1994;
Mautner et al. 1996b). The present study demonstrates
that the penetrance of meningiomas increases with in-
creasing age, after adjustment for the type of NF2 mu-
tation in a regression model. The genotype-phenotype
correlation of missense mutations with meningiomas is
of interest because missense mutations produce NF2
protein (termed “merlin” or “schwannomin”) that is
defective in negative growth regulation, whereas non-
sense mutations do not produce stable merlin (Gutmann
et al. 1998). Missense mutations also produce merlin
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Table 4
Genotype-Phenotype Correlations for Spinal Tumors
Type of NF2 Mutationa
Sample Average of No.
of Spinal Tumors
Model-Based Estimated
Average of No.
of Spinal Tumors
95% CI for Count
Ratiosb
Nonsense or frameshift:
Classical NF2 4.1 4.1 1.00c
Somatic mosaic 2.1 1.7 .21–1.16
Splice site 2.1 2.1 .26–.94
Missense 2.0 2.2 .23–1.99
Large deletion .8 .8 .10–.52
Unfound mutations:
Inherited cases 1.9 1.6 .15–1.06
People with new mutations:
Age at onset !20 years 6.1 4.5 .72–3.32
Age at onset 20 years 1.1 1.1 .13–.50
NOTE.—Statistically signiﬁcant results are shown in bold italics.
a Other covariates: Intrafamilial correlation (95% CI .10–.32). Current age (per year): 1.00coefficientp .21
(95% CI .97–1.03). Type of treatment center (specialty vs. nonspecialty): 2.42 (95% CI 1.62–8.70).
b Compared with people with classical NF2 and nonsense or frameshift mutations.
c Reference group.
with reduced but not absent binding with bII-spectrin
(Scoles et al. 1998), which may be caused by complex
conformational changes that alter merlin folding and
affect access to a binding site (Scoles et al. 2002).
Spinal tumors are found in up to 90% of patients with
NF2 when the full spine is scanned by MRI (Mautner
et al. 1995). In the present study, patients with NF2
who had been seen at specialty treatment centers had a
signiﬁcantly higher number of spinal tumors, after ad-
justment for the type of NF2 mutation and other co-
variates in a regression model. Patients with NF2 who
are seen at specialty treatment centers may be more
likely to have full spine MRI, which would lead to the
association of specialty treatment centers with a higher
number of spinal tumors. Intradural and extradural ex-
tramedullary spinal tumors in patients with NF2 are
usually schwannomas or meningiomas, whereas intra-
medullary tumors are usually ependymomas or astro-
cytomas. A previous study noted that intramedullary
spinal tumors were less common inNF2-affected patients
with several types of NF2 mutations in the aggregate
(splice-site mutations, missense mutations, or in-frame
deletions) than in those with nonsense or frameshift
mutations (Patronas et al. 2001). However, speciﬁc ge-
notype-phenotype correlations were not found in that
study.
Peripheral nerve tumors occur in about half of people
with NF2 (Mautner et al. 1997). The prevalence of pe-
ripheral nerve tumors is signiﬁcantly less in people with
mild NF2 than in those with severe NF2 (Mautner et
al. 1997). This is suggestive of genotype-phenotype cor-
relations, but, prior to this study, such correlations had
not been evaluated.
Spinal tumors and peripheral nerve tumors were less
common in people with somatic mosaicism than in peo-
ple with classical NF2 and constitutional NF2 nonsense
or frameshift mutations. Each of these types of tumors
was also less common in people with new unfound mu-
tations and older age at onset of symptoms than in
people in the reference group. The latter association is
not a speciﬁc genotype-phenotype correlation, because
patients with unfound NF2 mutations may have differ-
ent types of mutations. However, it is likely that most
of these patients have somatic mosaicism. A similar pat-
tern occurs in NF2-associated cataracts, which are less
common in people with somatic mosaicism or new un-
found mutations and older age at onset of symptoms
than in people with classical NF2 and constitutionalNF2
nonsense or frameshift mutations (Baser et al. 2003).
Somatic mosaicism occurs in an estimated 25%–30%
of patients with NF2 who have new mutations (Evans
et al. 1998b; Kluwe and Mautner 1998; Kluwe et al.
2003; Moyhuddin et al. 2003). The relatively low ef-
ﬁciency (∼60%) of conventional mutation screening
techniques in detecting constitutional NF2 mutations in
patients with NF2 who have new mutations has been
attributed to somatic mosaicism. In somatic mosaics,
conventional DNA sequencing of lymphocyte DNA
PCR product often fails to identify a difference from
the normal sequence because the mutant allele is present
at too low a level to be detected. In this study, somatic
mosaics with nonsense or frameshift mutations had sig-
niﬁcantly fewer peripheral nerve tumors than did people
with full constitutional NF2 nonsense or frameshift
mutations.
In this study, spinal tumors and peripheral nerve tu-
Baser et al.: Genotype-Phenotype Correlations in NF2 237
Table 5
Genotype-Phenotype Correlations for Non–VIII Nerve Cranial Nerve Tumors
Type of NF2 Mutationa
Sample Average of
Prevalence of Non–VIII
Nerve Cranial Nerve
Tumors (%)
Model-Based Estimated
Prevalence of Non–VIII
Nerve Cranial Nerve
Tumors (%) RRb 95% CI
Nonsense or frameshift:
Classical NF2 44 45 1.00c
Somatic mosaic 27 27 .37 .10–1.37
Splice-site 33 35 .60 .23–1.57
Missense 24 24 .31 .06–1.62
Large deletion 41 42 .85 .28–2.58
Unfound mutations:
Inherited cases 28 24 .31 .07–1.44
People with new mutations
Age at onset !20 years 54 54 1.54 .51–4.62
Age at onset 20 years 28 28 .39 .15–1.01
a Other covariates: Intrafamilial correlation (95% CI .13 to .64). Current age (percoefficientp .36
year): 1.00 (95% CI .85–1.17). Type of treatment center (specialty vs. nonspecialty): 1.00 (95% CI .28–
3.52).
b Compared with people with classical NF2 and nonsense or frameshift mutations.
c Reference group.
mors were less common in people with constitutional
NF2 large deletions than in people with constitutional
NF2 nonsense or frameshift mutations. There have been
other reports of mild NF2 in people with constitutional
NF2 large deletions (Lopez-Correa et al. 2000; Bruder
et al. 2001). ConstitutionalNF2 large deletions are found
in 21%–32% of families with NF2, when multiple
screening methods or microarray-comparative genomic
hybridization are used (Zucman-Rossi et al. 1998; Bru-
der et al. 2001). Conventional mutation screening tech-
niques such as SSCP analysis are unable to detect large
deletions in autosomal genes because those methods are
not designed to measure gene dosage. When a large
deletion is present, the normal allele alone is ampliﬁed
and analyzed; consequently, the deletion is cryptic to
the analytical method. A gene dosage method was used
to detect large deletions in this study.
Historically, NF2 disease severity was said to “run
true” in families, but some studies noted marked intra-
familial clinical variability (Kluwe and Mautner 1996;
Mautner et al. 1996a; Scoles et al. 1996). In a previous
study based on an international NF2 clinicomolecular
database, we found that there were strong intrafamilial
correlations for age at onset of hearing loss (all mutation
types, 0.51; families with missense mutations, 0.67),
and there were signiﬁcant but weaker intrafamilial cor-
relations for intracranial meningiomas (all mutation
types, 0.29; families with splice-site mutations, 0.39)
(Zhao et al. 2002). The present study conﬁrms this con-
clusion with respect to intracranial meningiomas in a
partially overlapping data set and additionally demon-
strates that there is a signiﬁcant (although weak) intra-
familial correlation for spinal tumors. These intrafam-
ilial correlations were observed in regression models
after adjustment for the type of mutation, and it is pos-
sible that the correlations reﬂect differences in the phe-
notypic effects produced by individual NF2 alleles that
comprise a mutation type. It is also possible that the
intrafamilial correlations are evidence of other genetic
loci that affect the NF2 phenotype. Other evidence sug-
gests that modifying genes may affect the clinical mani-
festations of NF2 (Bruder et al. 1999).
The type of constitutional NF2 mutation is an im-
portant determinant of the number of NF2-associated
intracranial meningiomas, spinal tumors, and peripheral
nerve tumors. Constitutional NF2 splice-site mutations
may have different effects, depending on the location
within the gene; that is, 3′ mutations may cause less
severe NF2 than do 5′ mutations (Kluwe et al. 1998).
Recent longitudinal studies have found that the age at
onset of symptoms of NF2 and age at diagnosis of NF2
are the strongest predictors of vestibular schwannoma
growth rates (Baser et al. 2002b; Mautner et al. 2002)
and the risk of mortality (Baser et al. 2002a; Otsuka et
al. 2003). People with constitutional NF2 missense mu-
tations have a lower risk of mortality than do those
with constitutional NF2 nonsense or frameshift muta-
tions (Baser et al. 2002a). Additional longitudinal ge-
notype-phenotype correlation studies of associations be-
tween the type of constitutional NF2 mutation and the
development of speciﬁc types of NF2-associated tumors
may provide information that is useful for the clinical
management of people with NF2.
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